| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl Basic information |
| Product Name: | N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl | | Synonyms: | 6-o-stearoyl-n-acetylmuramyl-alanylisoglutamine;N-acetylmuramyl-6-O-stearoyl-L-alanyl-*D-isogluta;N-ACETYLMURAMYL-6-O-STEAROYL-L-ALANYL-D-ISOGLUTAMINE);Ac-(6-O-stearoyl)-MuraMyl-Ala-D-Isogln-OH, L18-MDP;Ac-(6-O-stearoyl)-muramyl-Ala-D-Glu-NH;D-α-Glutamine, N-[N-acetyl-6-O-(1-oxooctadecyl)muramoyl]-L-alanyl-;N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl | | CAS: | 60398-08-5 | | MF: | C37H66N4O12 | | MW: | 758.94 | | EINECS: | | | Product Categories: | | | Mol File: | 60398-08-5.mol |  |
| | N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl Chemical Properties |
| Boiling point | 1036.044±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.155±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | −20°C | | pka | 4.442±0.10(predicted) | | Sequence | Ac-(6-O-stearoyl)-muramyl-Ala-{d-Glu}-NH2 |
| | N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl Usage And Synthesis |
| Uses | L18-MDP is a derivative of muramyl dipeptide, an antibacterial agent. L18-MDP has antibacterial activity and has potential applications in bacterial and fungal infections[1]. | | in vivo | L18-MDP (100 μg; s.c.; single dose) has anti-infection effect in mice infected with Escherichia coli or Klebsiella pneumoniae[1].
L18-MDP (100 μg or 1000 μg; s.c., i.p., i.v. or p.o.; single dose) increases the survival rate of mice infected with Escherichia coli and improves the pathological tissue of mice infected with Listeria monocytogenes[1].
L18-MDP (100 μg or 200 μg; s.c. or i.p.; once daily for 3 days) increases the survival rate of mice infected with Candida albicans[1].
| Animal Model: | Mice infected with Escherichia coli, Klebsiella pneumoniae or Listeria monocytogenes[1]. | | Dosage: | 100 μg or 1000 μg. | | Administration: | Subcutaneous injection, intraperitoneal injection, intravenous injection or oral gavage; single dose. | | Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
| Animal Model: | Mice infected with Candida albicans[1]. | | Dosage: | 100 μg or 200 μg. | | Administration: | Subcutaneous injection or intraperitoneal injection; once daily for 3 days. | | Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
| | References | [1] Osada Y, et al. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun. 1982 Jul;37(1):292-300. DOI:10.1128/iai.37.1.292-300.1982 |
| | N-Acetylmuramyl-L-alanyl-D-isoglutamine-6-O-stearoyl Preparation Products And Raw materials |
|